7月16日 - ** 癌症疗法制造商联想生物LEGN.O股价盘前上涨4.2%至41.25美元
** 合作伙伴强生JNJ.N公布第二季度血癌细胞疗法Carvykti的销售额为4.39亿美元，而一致预期为4.19亿美元。
** 强生公司称，Carvykti的增长主要得益于持续的份额增长和产能扩张。
** 我们期待 25 年下半年的持续增长，鉴于下半年的典型强劲表现，尤其是随着额外产量的可能投产，预计收入将加速增长。
** 我们看好 Carvykti 继续以 ~19% 的季度环比增长率增长，这表明骨髓瘤市场仍有未开发的需求，这将使其在下半年和 2026 年实现进一步增长，券商称。
** 截至上一交易日收盘，LEGN 年累计上涨 21.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.